Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Shares Jump 22 Percent After CEO Said Positive Cash Flow Likely

NEW YORK, July 13 (GenomeWeb News) - Shares in Transgenomic were up 22 percent, or $.17, at $.94 in late-afternoon trading after the company's CEO said the firm "should" reach neutral to positive operating cash flow by the end of the year.

 

Speaking to investors at Transgenomic's annual shareholder meeting today, Collin D'Silva said the company's recently completed restructuring will help the company "accelerate" revenue growth during the second half of the year, which he said would "approach" 20 percent on a year-over-year basis.

As GenomeWeb News reported last November, Transgenomic restructured its business and exited the oligonucleotide-manufacturing space in order to focus on its BioSystems segment.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.